Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoTTF-100L(P) System with Chemotherapy and Bevacizumab in Hepatic Metastatic Cancer
NCT03203525Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2020
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial in hepatic metastasis and colorectal cancer (CRC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events at 3 years. Started Jun 2020; status: terminated.
02
Conditions
hepatic metastasiscolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03203525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203525.